Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Non-Current Deffered Revenue (2018 - 2019)

Champions Oncology has reported Non-Current Deffered Revenue over the past 2 years, most recently at $851000.0 for Q2 2019.

  • For Q2 2019, Non-Current Deffered Revenue rose 87.44% year-over-year to $851000.0; the TTM value through Apr 2019 reached $851000.0, up 87.44%, while the annual FY2019 figure was $851000.0, 87.44% up from the prior year.
  • Non-Current Deffered Revenue for Q2 2019 was $851000.0 at Champions Oncology, up from $733000.0 in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $851000.0 in Q2 2019 and troughed at $454000.0 in Q2 2018.